P3.12-02 Dynamics of DLL3 and ASCL1 Expression in SCLC Over Disease Course

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1825
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.12-03 Targeting DLL3 With AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Ascl1 and Neurog2 Form Novel Complexes and Regulate Delta-Like3 (Dll3) Expression in the Neural Tube

Developmental Biology
Developmental BiologyCell BiologyMolecular Biology
2009English

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

Oncologist
Cancer ResearchMedicineOncology
2019English

P3.12-10 Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-01 Targeting Mitochondrial Metabolism as a Selective Therapeutic Approach in Small Cell Lung Cancer (SCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA13.02 Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-17 a Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) With Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.12-05 the Pattern of PD-L1 Expression in Thoracic Neuroendocrine Tumors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy